Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain
Coste-efectividad de la combinación dutasterida y tamsulosina en el tratamiento de la hiperplasia benigna de próstata en España
F. Antoñanzasa, F. Brenesb, J.M. Moleroc, A. Fernández-Prod, A. Huertae, R. Palenciae, J.M. Cozarf,
Corresponding author
a Departamento de Economía Aplicada, Universidad de la Rioja, Logroño, Spain
b Centro de Atención Primaria Llefià (ABS6), Badalona, Barcelona, Spain
c Centro de Salud San Andrés, Madrid, Spain
d Centro de Salud de Menasalbas, Toledo, Spain
e GlaxoSmithKline, Tres Cantos, Madrid, Spain
f Servicio de Urología, Hospital Universitario Virgen de las Nieves, Granada, Spain
Read
1521
Timeswas read the article
1419
Total PDF
102
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 18 | 18 |
| 2025 11 | 0 | 57 | 57 |
| 2025 10 | 0 | 54 | 54 |
| 2025 9 | 0 | 42 | 42 |
| 2025 8 | 0 | 59 | 59 |
| 2025 7 | 0 | 31 | 31 |
| 2025 6 | 0 | 26 | 26 |
| 2025 5 | 0 | 12 | 12 |
| 2025 4 | 0 | 32 | 32 |
| 2025 3 | 0 | 24 | 24 |
| 2025 2 | 0 | 22 | 22 |
| 2025 1 | 0 | 47 | 47 |
| 2024 12 | 0 | 12 | 12 |
| 2024 11 | 0 | 14 | 14 |
| 2024 10 | 0 | 12 | 12 |
| 2024 9 | 0 | 20 | 20 |
| 2024 8 | 0 | 17 | 17 |
| 2024 7 | 0 | 12 | 12 |
| 2024 6 | 0 | 11 | 11 |
| 2024 5 | 0 | 19 | 19 |
| 2024 4 | 0 | 2 | 2 |
| 2024 3 | 0 | 20 | 20 |
| 2024 2 | 0 | 2 | 2 |
| 2024 1 | 0 | 13 | 13 |
| 2023 12 | 0 | 19 | 19 |
| 2023 11 | 0 | 19 | 19 |
| 2023 10 | 0 | 30 | 30 |
| 2023 9 | 0 | 13 | 13 |
| 2023 8 | 0 | 9 | 9 |
| 2023 7 | 0 | 47 | 47 |
| 2023 6 | 0 | 14 | 14 |
| 2023 5 | 0 | 2 | 2 |
| 2023 4 | 0 | 13 | 13 |
| 2023 3 | 1 | 19 | 20 |
| 2023 2 | 0 | 6 | 6 |
| 2023 1 | 0 | 12 | 12 |
| 2022 12 | 0 | 7 | 7 |
| 2022 11 | 0 | 8 | 8 |
| 2022 10 | 0 | 5 | 5 |
| 2022 9 | 0 | 37 | 37 |
| 2022 8 | 0 | 12 | 12 |
| 2022 7 | 0 | 27 | 27 |
| 2022 6 | 0 | 4 | 4 |
| 2022 5 | 0 | 9 | 9 |
| 2022 4 | 0 | 18 | 18 |
| 2022 3 | 0 | 7 | 7 |
| 2022 2 | 0 | 8 | 8 |
| 2022 1 | 0 | 6 | 6 |
| 2021 12 | 0 | 11 | 11 |
| 2021 11 | 0 | 11 | 11 |
| 2021 10 | 0 | 14 | 14 |
| 2021 9 | 0 | 3 | 3 |
| 2021 8 | 0 | 5 | 5 |
| 2021 7 | 0 | 10 | 10 |
| 2021 6 | 0 | 9 | 9 |
| 2021 5 | 0 | 10 | 10 |
| 2021 4 | 0 | 18 | 18 |
| 2021 3 | 0 | 10 | 10 |
| 2021 2 | 0 | 7 | 7 |
| 2021 1 | 0 | 7 | 7 |
| 2020 12 | 0 | 6 | 6 |
| 2020 11 | 0 | 13 | 13 |
| 2020 10 | 0 | 6 | 6 |
| 2020 9 | 0 | 3 | 3 |
| 2020 8 | 0 | 5 | 5 |
| 2020 7 | 0 | 2 | 2 |
| 2020 6 | 0 | 17 | 17 |
| 2020 5 | 0 | 5 | 5 |
| 2020 4 | 0 | 9 | 9 |
| 2020 3 | 0 | 15 | 15 |
| 2020 2 | 0 | 11 | 11 |
| 2020 1 | 0 | 16 | 16 |
| 2019 12 | 0 | 15 | 15 |
| 2019 11 | 0 | 5 | 5 |
| 2019 10 | 0 | 6 | 6 |
| 2019 9 | 0 | 8 | 8 |
| 2019 8 | 0 | 5 | 5 |
| 2019 7 | 0 | 17 | 17 |
| 2019 6 | 0 | 21 | 21 |
| 2019 5 | 0 | 68 | 68 |
| 2019 4 | 0 | 25 | 25 |
| 2019 3 | 0 | 1 | 1 |
| 2019 2 | 0 | 4 | 4 |
| 2018 12 | 0 | 8 | 8 |
| 2018 11 | 0 | 4 | 4 |
| 2018 10 | 0 | 4 | 4 |
| 2018 9 | 0 | 1 | 1 |
| 2018 8 | 0 | 1 | 1 |
| 2018 6 | 0 | 1 | 1 |
| 2018 5 | 0 | 1 | 1 |
| 2018 2 | 2 | 1 | 3 |
| 2018 1 | 1 | 3 | 4 |
| 2017 12 | 5 | 2 | 7 |
| 2017 11 | 1 | 4 | 5 |
| 2017 10 | 6 | 1 | 7 |
| 2017 9 | 6 | 6 | 12 |
| 2017 8 | 2 | 11 | 13 |
| 2017 7 | 2 | 3 | 5 |
| 2017 6 | 5 | 2 | 7 |
| 2017 5 | 8 | 1 | 9 |
| 2017 4 | 7 | 4 | 11 |
| 2017 3 | 5 | 21 | 26 |
| 2017 2 | 3 | 0 | 3 |
| 2017 1 | 3 | 0 | 3 |
| 2016 12 | 8 | 2 | 10 |
| 2016 11 | 10 | 3 | 13 |
| 2016 10 | 13 | 4 | 17 |
| 2016 9 | 6 | 1 | 7 |
| 2016 8 | 7 | 3 | 10 |
| 2016 7 | 1 | 0 | 1 |
Show all
